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Elevated expression of TIGIT 
on CD3+CD4+ T cells correlates with disease 
activity in systemic lupus erythematosus
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Abstract 
Objectives: It is well-known that lymphocytes play an important role in systemic lupus erythematosus (SLE). T cell 
immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory domains (TIGIT) is one of immunosuppres-
sive costimulatory molecules that mediates an inhibitory effect. However, its roles in SLE are poorly understood. This 
study was designed to investigate the correlation between the frequencies of TIGIT-expressing CD3+CD4+ T lympho-
cytes and SLE.
Methods: Patients with SLE were recruited from the First Affiliated Hospital of Nanchang University. Medical history, 
clinical manifestations, physical examination and laboratory measurements were recorded. The expression of TIGIT on 
CD3+ T lymphocytes, B lymphocytes, monocytes, neutrophils, CD3+CD4+ T lymphocytes and CD3+CD8+ T lympho-
cytes were determined by flow cytometry. The frequencies of TIGIT-expressing CD3+CD4+ T lymphocytes in patients 
with SLE were further analyzed for correlations with markers of autoimmune response, inflammation, urine proteins 
and disease activity in SLE.
Results: The frequency of TIGIT-expressing CD3+CD4+ T lymphocytes was significantly elevated in SLE patients 
compared with healthy controls (P < 0.0001). The frequency of TIGIT-expressing CD3+CD4+ T lymphocytes in patients 
with SLE was increased significantly in subjects with high anti-dsDNA titer (P = 0.026), high anti-Sm titer (P = 0.026), 
and high levels of urine microalbumin (P = 0.046). Furthermore, The frequency of TIGIT-expressing CD3+CD4+ T 
lymphocytes was found to be positively correlated with the Disease Activity Index (SLEDAI) score in SLE (r2 = 0.082; 
P = 0.044).
Conclusion: In SLE, the frequency of TIGIT-expressing CD3+CD4+ T lymphocytes was elevated and associated with 
the disease activity.
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Background
Systemic lupus erythematosus (SLE) is a prototypic sys-
temic autoimmune disease characterized by the produc-
tion of autoantibodies, deposition of immune complexes 
in various organs and potentially causing life-threat-
ening renal, cardiac or brain damage [1, 2]. The mecha-
nisms underlying SLE are complex, including genetic 
and environmental factors and abnormalities of both 
the innate and the adaptive immune systems [3]. Pivotal 
in the pathogenesis of lupus is the production of high-
affinity pathogenic autoantibodies such as anti-double 
stranded DNA (anti-dsDNA) and anti-Smith (anti-Sm) 
[4]. Evidences from both human studies and animal mod-
els have demonstrated that both autoantibodies produc-
tion and SLE pathogenesis are dependent on CD4+ T 
cells [5, 6]. Recently, some researches indicated that T 
cells with abnormal costimulatory molecules could acti-
vate autoantibody-producing B cells, suggesting the piv-
otal role of costimulatory molecules in the pathogenesis 
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of SLE. Revealing the abnormalities of costimulatory mol-
ecule expression on immune cells is therefore crucial for 
understanding the mechanisms of SLE [7].
Costimulatory molecules have been proven to regu-
late the functional outcome of T cell activation. T cell 
immunoreceptor with Ig and immunoreceptor tyros-
ine-based inhibitory domains (TIGIT), also known 
as WUCAM, VSIG9 or VSTM3, is a newly identified 
inhibitory type 1 transmembrane protein. The poliovirus 
receptor (PVR, also known as CD155) has been identi-
fied as the physical ligand of TIGIT. The interaction of 
PVR, which is expressed mainly on antigen-presenting 
cells (APC), and TIGIT could mediate inhibitory effects 
on TIGIT-expressing cells [8]. In mouse model, loss of 
TIGIT resulted in hyperproliferative T cell responses 
and increased susceptibility to autoimmune diseases [9]. 
As expected, TIGIT was reported to inhibit the activa-
tion of T cells and NK cells, manifested by downregulat-
ing cytokines secretion by T cells and the cytotoxicity 
of NK cells [8, 10–12]. Furthermore, the levels of TIGIT 
on NK cells are significantly lower in patients with SLE 
than healthy individuals, and associated with the increase 
of IFN-γ-producing NK cells in patients with SLE [13]. 
However, the expression and roles of TIGIT on other 
immune cells in the condition of SLE are unclear yet.
In the present study, we detected the expression of 
TIGIT on peripheral blood leucocytes and quantified 
the proportions of TIGIT-expressing peripheral T subset 
cells in patients with SLE. The correlation between the 
frequency of TIGIT-expressing CD3+CD4+ T lympho-
cytes and the activity of SLE was also evaluated.
Methods
Subjects
50 patients fulfilled the revised American College of 
Rheumatology criteria for SLE [14] were enrolled from 
the First Affiliated Hospital of Nanchang University 
from June 2015 to December 2015. Disease activity was 
assessed by the SLE disease activity index (SLEDAI) [15, 
16]. In addition, this study included 27 healthy controls 
(HCs) who were unrelated to the patients and who did 
not have inflammatory or autoimmune diseases. The 
study was approved by the Ethics Committee of the First 
Affiliated Hospital of Nanchang University (052) and was 
carried out in compliance with the Helsinki Declaration. 
Informed consent was obtained from all participants 
before they entered the study.
Flow cytometry analysis
Fresh peripheral blood specimens were collected from 
patients with SLE and HCs. The molecular phenotypes 
of peripheral blood leucocytes were analyzed imme-
diately using flow cytometry. The following antibodies 
were used: ECD-conjugated anti-CD3, PC5-conjugated 
anti-CD8, FITC-conjugated anti-CD4, PC5-conjugated 
anti-CD15, ECD-conjugated anti-CD14, PC5-conjugated 
anti-CD19 (BD Biosciences, San Diego CA, USA) and 
PE-conjugated anti-TIGIT (MIH clones, e Bioscience, 
San Diego, CA, USA). Briefly, 100 μL of fresh peripheral 
blood was incubated simultaneously with 10 μL of ECD-
conjugated anti-CD3, 10 μL of PC5-conjugated anti-CD8, 
10  μL of FITC-conjugated anti-CD4 and PE-conjugated 
anti-TIGIT or with 10 μL of ECD-conjugated anti-CD3, 
10  μL of PC5-conjugated anti-CD15 and PE-conjugated 
anti-TIGIT or with 10 μL of ECD-conjugated anti-CD14, 
10  μL of PC5-conjugated anti-CD19 and PE-conjugated 
anti-TIGIT on ice in the dark for 30 min. Cells incubated 
with PE-conjugated mouse IgG were used as isotype 
controls. RBCs were lysed with an ammonium-chloride-
potassium lysing buffer, and samples were washed and 
analyzed using a CYTOMICS FC 500 flow cytometer 
(BECKMAN COULTER) and associated software pro-
grams (CXP).
Autoantibody measurement
Anti-dsDNA of IgG in serum were measured using com-
mercially available ELISA kits (Kexin, Shanghai, China). 
Anti-extractable nuclear antigens (ENAs) antibod-
ies including anti-SSA, anti-SSB, anti-Ro52, anti-Sm, 
anti-nRNP/Sm, anti-rRNP, and anti-nucleosome anti-
body were determined using immunoenzyme dot assay 
(Euroimmun, Germany) according to the manufacturer’s 
instructions. The results of anti-ENAs detection were 
showed in negative (−) and positive (+, ++, +++) man-
ner by EuroBlot One.
Serum IgG, C3, C4 and urine protein measurement
The concentrations of serum immunoglobulin G (IgG), 
Complement 3 (C3), Complement 4 (C4) and urine 
protein including urine a1-microglobulin (a1-M), urine 
microalbumin (MALB), urine IgG (IGU) and urine trans-
ferring (TRU) were determined using nephelometry 
methods according to the instructions described by the 
manufacturer (IMMUNE800, Beckman, American).
ESR, urine routine, blood routine measurement
Erythrocyte sedimentation rate (ESR), urine routine and 
blood routine were determined according to the instruc-
tions described by the manufacturer.
Statistical analysis
Statistical analysis and graphic presentation were car-
ried out with GraphPad Prism version 5.0 (GraphPad 
Software, San Diego, CA). A t test was used if a normal-
ity test was passed; otherwise, the nonparametric Mann–
Whitney test was used to analyze the data. Likewise, the 
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The characteristics of SLE patients and healthy subjects 
(HCs) enrolled in this study are shown in Table 1. There 
were no significant differences between patients and HCs 
regarding age or gender. Patients with SLE were classified 
into inactive group (SLEDAI: 0–9) and active group (SLE-
DAI  ≥  10) according to SLEDAI [15, 16]. Overall, 32% 
of SLE patients are active patients. The two groups differ 
significantly in SLEDAI score, incidence of serum levels 
of anti-dsDNA, C3 and the proportion of circulating lym-
phocytes (all P < 0.05) (Table 2). Among them, 16 patients 
were new-onset SLE. The new-onset SLE and re-visiting 
SLE groups differ significantly in incidence of serum levels 
of anti-dsDNA, C3 and ESR (all P < 0.05) (Table 3).
T lymphocyte subsets in patients with SLE and HCs
While SLE patients showed a significantly lower pro-
portion of circulating lymphocytes than HCs (17.2 vs 
Table 1 Clinical characteristics and  proportions of  lym-
phocyte subsets in  peripheral blood of  patients with  SLE 
and HCs
a1-M urinea1-microglobulin, ANA anti-nuclear antibodies, Anti-dsDNA anti 
double-stranded DNA, Anti-SSA anti-SSA antigen, Anti-SSB anti-SSB antigen, 
C3 complement 3, C4 complement 4, ESR erythrocyte sedimentation rate, 
HCs healthy controls IgG immunoglobulin G, IGU urine IgG, MALB urine 
microalbumin, RNP ribonucleoprotein, rRNP ribosomal RNP, SLE systemic 
lupus erythematosus, SLEDAI SLE disease activity index, Sm Smith, TRU urine 
transferrin
* P < 0.05 compared to healthy control group
a Percentage of total white blood cells in peripheral blood
b Percentage of total lymphocytes in peripheral blood
c Percentage of CD3+ lymphocytes in peripheral blood
Categories SLE (n = 50) HCs (n = 27)
Females, n (%) 46 (92) 23 (85)
Age, mean (SD), years 35.5 ± 13.8 33.7 ± 10.8
SLEDAI score, mean (SD) 6.3 ± 4.9 –
ANA (+, ≥1:100), n (%) 49 (98.0) –
ds-DNA (+, >100 IU/mL), n (%) 19 (38.0) –
Anti-ENA (44 patients)
 Anti-Sm, n (%) 18 (40.9) –
 Anti-Ro52, n (%) 28 (63.6) –
 Anti-nRNP/Sm, n (%) 28 (63.6) –
 Anti-rRNP, n (%) 21 (47.7) –
 Anti-nucleosome, n (%) 16 (36.4) –
 Anti-SSA, n (%) 37 (84.1) –
 Anti-SSB, n (%) 11 (25.0) –
Decreased C3/C4, n (%) 37 (74.0)/30 (60.0) –
Increased IgG, n (%) 26 (52.0) –
Elevated ESR, n (%) 29 (58.0) –
Urine protein (20 patients)
 a1-M > 12.5 mg/L, n (%) 13 (65.0)
 MALB > 20 mg/L, n (%) 11 (55.0)
 IgU > 8 mg/L, n (%) 11 (55.0)
 TRU > 2 mg/L, n (%) 9 (45.0)
Clinical features
 Fever, n (%) 8 (16.0) –
 Cutaneous manifestations, n (%) 18 (36.0) –
 Oral ulcer, n (%) 5 (10.0) –
 Alopecia, n (%) 10 (20.0) –
 Arthritis, n (%) 16 (32.0) –
 Raynaud’s phenomenon, n (%) 9 (18.0) –
 Effusion, n (%) 6 (12.0) –
 Renal involvement, n (%) 19 (38.0) –
 Hematologic disorder, n (%) 32 (64.0) –
Lymphocytes, mean (SD), %a 17.2 (9.4)* 23.7 (6.7)
CD3+ lymphocytes, mean (SD), %b 69.9 (12.2)* 63.4 (7.8)
CD4+ T subset, mean (SD), %c 45.9 (12.9)* 54.4 (9.2)
CD4+ T subset, mean (SD), /mL 313.4 (34.2)* 423.4 (31.3)
CD8+ T subset, mean (SD), %c 38.2 (12.8)* 28.9 (6.5)
CD8+ T subset, mean (SD), /mL 419.4 (59.1) 432.4 (64.9)
Ratio of CD4+/CD8+T, mean (SD) 0.98 (0.58)* 1.29 (0.52)
Table 2 Demographic and  clinical data for  Chinese 
patients with active or inactive SLE
ANA anti-nuclear antibodies, Anti-dsDNA anti double-stranded DNA, C3 
complement 3, C4 complement 4, ESR erythrocyte sedimentation rate, IgG 
immunoglobulin G, SLE systemic lupus erythematosus, SLEDAI SLE disease 
activity index
* P < 0.05 compared to inactive SLE group
a Percentage of total white blood cells in peripheral blood
b Percentage of total lymphocytes in peripheral blood
c Percentage of CD3+ lymphocytes in peripheral blood
Categories Active SLE Inactive SLE
N 16 34
Females, n (%) 16 (100) 30 (88.2)
Age, mean (SD), years 32.8 (9.4) 36.7 (15.1)
ANA (+, ≥1:100), n (%) 16 (100) 33 (97.1)
Anti-dsDNA, mean (SD), IU/mL 355.8 (328.4)* 148.4 (239.9)
IgG, mean (SD), g/L 19.6 (9.8) 16.8 (7.9)
C3, mean (SD), g/L 0.45 (0.23)* 0.66 (0.26)
C4, mean (SD), g/L 0.11 (0.062) 0.14 (0.060)
ESR, mean (SD), mm/h 63.1 (44.1) 34.2 (35.5)
SLEDAI score, mean (SD) 12.6 (2.4)* 3.6 (2.8)
Lymphocytes, mean (SD), %a 12.0 (1.7)* 19.5 (1.9)
CD3+ lymphocytes, mean (SD), %b 73.2 (2.7) 68.2 (2.5)
CD4+ T subset, mean (SD), %c 42.5 (4.4) 47.3 (2.7)
CD4+ T subset, mean (SD), /mL 243.5 (69.6) 343.4 (38.2)
CD8+ T subset, mean (SD), %c 59.1 (4.0) 53.1 (2.6)
CD8+ T subset, mean (SD), /mL 336.1 (80.0) 455.1 (77.1)
Ratio of CD4+/CD8+ T, mean (SD) 0.81 (0.17) 1.12 (0.15)
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23.7%; P = 0.0053) (Table 1), the proportion of CD3+ T 
lymphocytes in total circulating lymphocytes was higher 
in SLE patients than HCs (69.9 vs 63.4%; P  =  0.016) 
(Table  1). Further analysis showed that, the proportion 
of CD3+CD4+ T lymphocytes in CD3+ lymphocytes was 
significantly decreased in patients with SLE compared 
to HCs (45.9 vs 54.4%; P  =  0.0094) (Table  1), and the 
proportion of CD3+CD8+ T lymphocytes in CD3+ lym-
phocytes was significantly elevated in patients with SLE 
compared to HCs (38.2 vs 28.9%; P = 0.0093) (Table 1). 
Moreover, the absolute CD3+CD4+ T lymphocytes num-
bers was significantly decreased in patients with SLE 
compared to HCs (313.4 vs 446.2; P = 0.0042) (Table 1), 
but no difference was found in the absolute CD3+CD8+ 
T lymphocytes numbers (Table 1). As a result, the ratio 
of CD3+CD4+ T cells to CD3+CD8+ T cells was sig-
nificantly lower in SLE patients (0.98 vs 1.29; P = 0.043) 
(Table 1).
The frequency of TIGIT‑expressing peripheral blood 
leucocytes in SLE patients and HCs
To determine the expression profile of TIGIT in SLE 
patients and HCs, we used flow cytometry to assess the 
expression of TIGIT on peripheral blood leucocytes 
including CD3+CD4+ T lymphocytes, CD3+CD8+ T 
lymphocytes, B lymphocytes, monocytes and neutro-
phils. Data showed that although the absolute number of 
TIGIT-expressing CD3+CD4+ T lymphocytes decreased, 
the frequency of TIGIT-expressing CD3+CD4+ T lym-
phocytes was significantly elevated in patients with SLE 
compared to HCs (P  <  0.0001) (Fig.  1). No significant 
difference was observed in the frequency of TIGIT-
expressing CD3+CD8+ T lymphocytes, monocytes and 
neutrophils between SLE individuals and HCs (Fig.  1). 
And, B lymphocytes had no apparent TIGIT expression. 
Further, results showed the frequency of TIGIT-express-
ing CD3+CD8+ T lymphocytes was significantly elevated 
compared to CD3+CD4+ T lymphocytes in both SLE 
patients (P < 0.0001) (Fig. 1) and HCs (P < 0.0001) (Fig. 1). 
The mean fluorescence intensity (MFI) of TIGIT in 
CD3+CD4+ T lymphocytes and CD3+CD8+ T lympho-
cytes from SLE patients and HCs was also determined, 
but no significant difference was found (data not shown).
The frequency of TIGIT‑expressing CD3+CD4+ T 
lymphocytes correlated with markers of T cell activation 
and other costimulatory molecules
We next tried to determine whether the TIGIT expres-
sion level is related to activation markers of T lympho-
cytes. Data showed that the frequency of CD69-expressing 
CD3+CD4+ T lymphocytes was significantly elevated in 
patients with SLE compared to HCs (P = 0.019) (Fig. 2a). 
No significant difference was observed in the frequency 
of CD69-expressing CD3+CD8+ T lymphocytes between 
SLE individuals and HCs (Fig.  2). Furthermore, results 
showed the frequency of CD69-expressing CD3+CD4+ 
TIGIT+ T lymphocytes was significantly elevated com-
pared to CD3+CD4+ TIGIT− T lymphocytes in SLE 
patients (P = 0.023) (Fig. 2c). Our results suggest that the 
TIGIT expression level is related to the activation of CD4 T 
lymphocytes.
Evidences from our studies and other reports indicated 
that PD1/PD-L1 play an important role in SLE [17–19]. 
In the current study, our results showed that the frequen-
cies of PD1-expressing CD3+CD4+ T lymphocytes and 
CD3+CD8+ T lymphocytes were significantly elevated 
in SLE patients compared to HCs (P < 0.05) (Fig. 2d, e). 
The frequencies of PD-L1-expressing CD3+CD4+ T 
lymphocytes and CD3+CD8+ T lymphocytes were also 
significantly elevated in SLE patients compared to HCs 
(P  <  0.05) (Fig.  2g, h). We further investigated the rela-
tionship between the PD1/PD-L1 expression levels and 
TIGIT expression level in CD3+CD4+ T lymphocytes. 
Data showed the percentages of PD1+ and PD-L1+ cells 
were not significantly different between TIGIT− and 
TIGIT+ CD3+CD4+ T lymphocytes (Fig. 2f, i).
Table 3 Demographic and  clinical data for  Chinese 
patients with new-onset and re-visiting SLE
ANA anti-nuclear antibodies, Anti-dsDNA anti double-stranded DNA, C3 
complement 3, C4 complement 4, ESR erythrocyte sedimentation rate, IgG 
immunoglobulin G, SLE systemic lupus erythematosus, SLEDAI SLE disease 
activity index
* P < 0.05 compared to re-visiting SLE group
a Percentage of total white blood cells in peripheral blood
b Percentage of total lymphocytes in peripheral blood
c Percentage of CD3+ lymphocytes in peripheral blood
Categories New‑onset SLE Re‑visiting SLE
N 16 34
Females, n (%) 15 (93.8) 31 (91.4)
Age, mean (SD), years 28.1 (11.1) 38.2 (14.6)
ANA (+, ≥1:100), n (%) 16 (100) 33 (97.1)
Anti-dsDNA, mean (SD), IU/mL 346.6 (329.3)* 165.3 (267.7)
IgG, mean (SD), g/L 19.1 (5.9) 17.0 (9.6)
C3, mean (SD), g/L 0.52 (0.33) 0.63 (0.23)
C4, mean (SD), g/L 0.09 (0.060)* 0.16 (0.050)
ESR, mean (SD), mm/h 62.1 (41.2)* 35.1 (38.0)
SLEDAI score, mean (SD) 8.4 (5.0) 5.5 (4.8)
Lymphocytes, mean (SD), %a 17.1 (1.0) 16.8 (7.9)
CD3+ lymphocytes, mean (SD), %b 68.3 (11.0) 70.3 (9.9)
CD4+ T subset, mean (SD), %c 40.8 (5.4) 47.8 (14.9)
CD4+ T subset, mean (SD), /mL 269.5 (8.7) 330.1 (239.4)
CD8+ T subset, mean (SD), %c 59.2 (5.4) 52.2 (14.9)
CD8+ T subset, mean (SD), /mL 435.8 (97.5) 455.1 (77.1)
Ratio of CD4+/CD8+T, mean (SD) 1.02 (0.85) 1.03 (0.64)
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Fig. 1 TIGIT expression on T lymphocytes subsets, monocytes and neutrophils. a Representative dot plots of population gating and TIGIT express-
ing cells from SLE patients and control subjects. Percentages of TIGIT expressing cells among CD3+CD4+, CD3+CD8+, CD14+ or CD15+CD3− cells 
are shown. b Summary data of the positive cell frequency in gated CD3+CD4+ cells, CD3+CD8+ cells, monocytes or neutrophils
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The frequency of TIGIT‑expressing CD3+CD4+ T 
lymphocytes correlated with markers of autoimmune 
response and inflammation marker
Anti-dsDNA and anti-ENAs, the hallmark antibodies of 
SLE, were determined and analyzed for their correlations 
with the frequency of TIGIT-expressing CD3+CD4+ 
T lymphocytes in this study. Data showed that 19 sub-
jects were positive for anti-dsDNA in all recruited SLE 
patients. 44 patients were tested for anti-ENAs in all 
recruited SLE patients and 43 patients were positive for 
at least one anti-ENA. Although there is no obvious cor-
relation between the frequency of TIGIT-expressing 
CD3+CD4+ T lymphocytes and anti-dsDNA level 
(data not shown), the frequency of TIGIT-expressing 
CD3+CD4+ T lymphocytes was significantly increased 
in patients with positive anti-dsDNA compared to 
patients with negative anti-dsDNA (P = 0.046) (Fig. 3a). 
Moreover, the correlation between the frequency of 
TIGIT-expressing CD3+CD4+ T lymphocytes and anti-
ENAs including anti-SSA, anti-SSB, anti-Ro52, anti-Sm, 
anti-nRNP/Sm, anti-rRNP, and anti-nucleosome were 
also investigated in SLE patients. As shown in Fig.  3b, 
the frequency of TIGIT-expressing CD3+CD4+ T lym-
phocytes was significantly increased in patients with 
Fig. 2 Correlation of frequency of TIGIT-expressing CD3+CD4+ T lymphocytes with markers of T cell activation and other costimulatory mol-
ecules. a The frequency of CD69-expressing CD3+CD4+ T lymphocytes was significantly increased in SLE patients compared to HCs (P = 0.019). b 
The frequency of CD69-expressing CD3+CD8+ T lymphocytes was similar between HCs and SLE (P = 0.69). c The frequency of CD69-expressing 
CD3+CD4+ TIGIT+ T lymphocytes was significantly elevated compared to CD3+CD4+ TIGIT− T lymphocytes in SLE patients (P = 0.023). d The 
frequency of PD1-expressing CD3+CD4+ T lymphocytes was significantly increased in SLE patients compared to HCs (P = 0.013). e The frequency 
of PD1-expressing CD3+CD8+ T lymphocytes was significantly increased in SLE patients compared to HCs (P = 0.0024). f The frequency of PD1-
expressing CD3+CD4+ TIGIT+ T lymphocytes was similar to CD3+CD4+ TIGIT− T lymphocytes (P = 0.94). g The frequency of PD-L1-expressing 
CD3+CD4+ T lymphocytes was significantly increased in SLE patients compared to HCs (P = 0.0004). h The frequency of PD-L1-expressing 
CD3+CD8+ T lymphocytes was significantly increased in SLE patients compared to HCs (P < 0.0001). i The frequency of PD-L1-expressing 
CD3+CD4+ TIGIT+ T lymphocytes was similar to CD3+CD4+ TIGIT− T lymphocytes (P = 0.27)
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positive anti-Sm compared to patients with negative anti-
Sm (P  =  0.026). No obvious correlation was observed 
between the frequency of TIGIT-expressing CD3+CD4+ 
T lymphocytes and other anti-ENAs (data not shown).
Patients with SLE frequently have abnormal levels of 
inflammatory markers, such as IgG, C3, C4 and ESR. In 
order to investigate the correlations between the frequency 
of TIGIT-expressing CD3+CD4+ T lymphocytes and 
inflammatory markers, inflammation markers including 
serum IgG, C3, C4 and ESR were determined and analyzed 
for their correlations with the frequency of TIGIT-express-
ing CD3+CD4+ T lymphocytes in patients with SLE. In 
general, there was no correlation between increased fre-
quency of TIGIT-expressing CD3+CD4+ T lymphocytes 
with serum IgG, C3, C4 and ESR (data not shown).
The frequency of TIGIT‑expressing CD3+CD4+ T 
lymphocytes correlated with urine protein
The results demonstrated that the frequency of TIGIT-
expressing CD3+CD4+ T lymphocytes was correlated 
with markers of autoimmune response, such as anti-
dsDNA. Anti-dsDNA is pathogenic autoantibody with 
the potential to result in renal damage [3, 20–22]. Thus, 
we investigated the correlation between the frequency 
of TIGIT-expressing CD3+CD4+ T lymphocytes and 
renal damage (characterized by proteinuria, hematu-
ria, or >5 leukocytes/hpf excluding infection [23–25]). 
Disappointing, no obvious correlation was observed 
between the frequency of TIGIT-expressing CD3+CD4+ 
T lymphocytes and proteinuria, hematuria, pyuria in this 
study. Next, the correlations between the frequency of 
TIGIT-expressing CD3+CD4+ T lymphocytes and the 
quantificational levels of urine protein, including urine 
a1-M, urine microalbumin (MALB), urine IgG (IGU) and 
urine transferrin (TRU), were analyzed in 20 patients 
with SLE. As shown in Fig.  4, positive correlations 
between the frequency of CD3+CD4+ T lymphocytes 
and the levels of MALB (r2 = 0.33; P = 0.0081) (Fig. 4a), 
IgU (r2 = 0.26; P = 0.021) (Fig. 4c) and TRU (r2 = 0.24; 
P  =  0.027) (Fig.  4d) were found. No obvious correla-
tion was observed between the frequency of TIGIT-
expressing CD3+CD4+ T lymphocytes and a1-M (data 
not shown). Moreover, we found that the frequency of 
TIGIT-expressing CD3+CD4+ T lymphocytes was sig-
nificantly increased in patients with urine MALB levels 
>20  mg/L (P  =  0.046) (Fig.  4b). And, the frequency of 
TIGIT-expressing CD3+CD4+ T lymphocytes trends to 
elevate in patients with higher a1-M, IgU and TRU (data 
not shown) respectively, but significant difference was 
not reached.
The frequency of TIGIT‑expressing CD3+CD4+ T 
lymphocytes correlated with disease activity of SLE
Our results demonstrated that the frequency of TIGIT-
expressing CD3+CD4+ T lymphocytes was correlated 
with markers of autoimmune response. Some of these 
markers such as anti-dsDNA, is traditionally valuable 
for monitoring disease activity in patients with SLE [22]. 
Thus, patients with SLE were further classified as active 
and inactive patients according to the SLEDAI and the 
correlation between the frequency of TIGIT-expressing 
CD3+CD4+ T lymphocytes and disease activity was ana-
lyzed. Data showed that the frequency of TIGIT-express-
ing CD3+CD4+ T lymphocytes in patients with active 
SLE was significantly higher compared with patients with 
inactive SLE (P = 0.04) (Fig. 5a). Furthermore, there was 
a positive correlation between the frequency of TIGIT-
expressing CD3+CD4+ T lymphocytes and the SLEDAI 
score (r2 = 0.082; P = 0.044) (Fig. 5b). These results thus 
demonstrated that the frequency of TIGIT-expressing 
CD3+CD4+ T lymphocytes was correlated with disease 
activity of SLE.
Fig. 3 Correlation of frequency of TIGIT-expressing CD3+CD4+ T lymphocytes with autoantibody. a The frequency of TIGIT-expressing CD3+CD4+ 
T lymphocytes was significantly increased in SLE patients positive to anti-dsDNA (P = 0.046). b The frequency of TIGIT-expressing CD3+CD4+ T 
lymphocytes was significantly increased in SLE patients positive to anti-Sm (P = 0.027)
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Subsequently, we compared the frequency of TIGIT-
expressing CD3+CD4+ T lymphocytes between new-
onset and re-visiting SLE patients. Data showed that the 
frequency of TIGIT-expressing CD3+CD4+ T lympho-
cytes tends to be elevated in new-onset patients, but a 
significant difference was not reached (Fig. 5c).
Although the frequency of TIGIT-expressing 
CD3+CD4+ T lymphocytes was associated with disease 
activity of SLE, it was not associated with clinical features 
of patients with SLE including fever, cutaneous mani-
festations, oral ulcer, alopecia, arthritis, Raynaud’s phe-
nomenon, effusion, and hematologic disorder (data not 
shown).
Discussion
Systemic lupus erythematosus (SLE) is a systemic auto-
immune syndrome with unclear etiology. Costimulatory 
molecules were reported to play important roles in SLE 
[13, 26]. Program death-1 and program death-1 ligands 
(PD1/PD-L1), which have been proven to play a major 
role in suppressing immune response, were found to be 
elevated expressed on T cells of patients with SLE [17, 18]. 
T cell immunoglobulin domain- and mucin domain con-
taining molecule-3 (Tim-3), a co-inhibitory type 1 trans-
membrane protein, has been identified to be expressed at 
high levels on T cells and associated with disease activity 
in SLE patients [27]. Cytotoxic T-lymphocyte-associated 
antigen-4 (CTLA-4), a member of the immunoglobulin 
superfamily that can downregulate T-cell function, was 
found to be increased on T cells, and CTLA-4 dysfunc-
tion has been identified as a potential cause for abnormal 
T-cell activation in patients with SLE [28]. In addition, 
CD40 ligand (CD40L) and many other inhibitory recep-
tors could also be expressed on T cells in SLE [29, 30]. 
TIGIT is a newly identified inhibitory type 1 transmem-
brane protein expressed on immune cells. In this study, 
for the first time, we investigated the expression of 
TIGIT on neutrophils, monocytes, B and T lymphocytes 
from patients with SLE, and showed that the frequency 
of TIGIT-expressing CD3+CD4+ T lymphocytes was 
Fig. 4 Correlation of frequency of TIGIT-expressing CD3+CD4+ T lymphocytes with urine protein. a The frequency of TIGIT-expressing CD3+CD4+ T 
lymphocytes in SLE patients correlated significantly with MALB (r2 = 0.33; P = 0.0081). b The frequency of TIGIT-expressing CD3+CD4+ T lympho-
cytes was significantly increased in SLE patients with MALB >20 mg/L (P = 0.046). c The frequency of TIGIT-expressing CD3+CD4+ T lymphocytes in 
SLE patients correlated significantly with IgU (r2 = 0.26; P = 0.021). d The frequency of TIGIT-expressing CD3+CD4+ T lymphocytes in SLE patients 
correlated significantly with TRU (r2 = 0.24; P = 0.027)
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significantly increased in patients with SLE compared 
with HCs. Moreover, our research revealed that the fre-
quency of TIGIT-expressing CD3+CD4+ T lymphocytes 
was associated with disease activity of SLE.
Lymphocytes were reported to play important roles 
in the development and progression of disease [31, 32]. 
Consistent with previous studies [33, 34], our study 
found a lower proportion of CD3+CD4+ T cells and 
higher proportion of CD3+CD8+ T cells in SLE patients. 
And, we found that the frequency of TIGIT-expressing 
CD3+CD8+ T lymphocytes was significantly elevated 
compared to CD3+CD4+ T lymphocytes. No signifi-
cant difference was observed in the frequency of TIGIT-
expressing CD3+CD8+ T lymphocytes between SLE 
patients and HCs, while the frequency of TIGIT-express-
ing CD3+CD4+ T lymphocytes were significantly ele-
vated in patients with SLE compared to HCs. It supports 
the observations that SLE involves an imbalance of T cell 
subsets and that the abnormal expression of key signaling 
molecules on T lymphocytes plays an important role in 
SLE pathogenesis [35].
In addition to imbalance of T cell subsets, another char-
acteristic of SLE is dysregulated activation of T lympho-
cytes. CD69 is an early cell activation marker that could 
show the quantity of active immune cells in the disease 
activity [36]. And, CD69 was usually used to evaluate the 
activation of T lymphocytes in SLE. Other reports [36, 
37] and our results showed that the frequency of CD69-
expressing CD3+CD4+ T lymphocytes was significantly 
elevated in patients with SLE. Moreover, we found that 
the frequency of CD69-expressing CD3+CD4+ TIGIT+ 
T lymphocytes was significantly elevated compared to 
CD3+CD4+ TIGIT− T lymphocytes in SLE patients. 
Our results suggest that the TIGIT expression level is 
related to activation of CD3+CD4+ T lymphocytes. It 
supports the fact that the frequency of TIGIT-expressing 
CD3+CD4+ T lymphocytes was associated with disease 
activity of SLE and dysregulated activation of T lympho-
cytes involves in SLE pathogenesis.
Indeed, TIGIT was shown to be involved in the B cell 
regulation and antibodies production by regulating the 
interactions between T cells and follicular dendritic 
cells [38, 39]. It is well-known that SLE is a systemic 
Fig. 5 Correlation of frequency of TIGIT-expressing CD3+CD4+ T lymphocytes with disease activity. a The frequency of TIGIT-expressing CD3+CD4+ 
T lymphocytes in SLE patients was significantly increased in active SLE patients compared to inactive SLE patients (P = 0.04). b The frequency of 
TIGIT-expressing CD3+CD4+ T lymphocytes in SLE patients correlated significantly with SLEADI (r2 = 0.082; P = 0.044). c The frequency of TIGIT-
expressing CD3+CD4+ T lymphocytes tends to be elevated in new-onset patients of SLE, but a significant difference was not reached (P = 0.28)
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autoimmune diseases characterized by elevated auto-
immune antibodies, such as anti-dsDNA and anti-Sm. 
In this study, the serous levels of anti-dsDNA and anti-
ENAs including anti-SSA, anti-SSB, anti-Ro52, anti-Sm, 
anti-nRNP/Sm, anti-rRNP, and anti-nucleosome, were 
determined and analyzed for their relationship with 
the frequency of TIGIT-expressing CD3+CD4+ T lym-
phocytes. Data showed that the frequency of TIGIT-
expressing CD3+CD4+ T lymphocytes was significantly 
increased in patients with positive anti-dsDNA and 
anti-Sm, suggesting that TIGIT-expressing CD3+CD4+ 
T lymphocytes might be associated with autoimmune 
responses in SLE.
Anti-dsDNA is one of pathogenic autoantibodies 
which was reported to involve in renal damage [22]. So 
next we investigated the association between TIGIT-
expressing CD3+CD4+ T lymphocytes and renal dam-
age. Due to low compliance of renal biopsy, proteinuria, 
hematuria, Pyuria et al. were chosen to evaluate the renal 
damage. Results showed that the frequency of TIGIT-
expressing CD3+CD4+ T lymphocytes was positively 
correlated with MALB. This supported the correlation 
between the frequency of TIGIT-expressing CD3+CD4+ 
T lymphocytes and renal damage of SLE patients. Sub-
sequent results resulted from the SLEDAI classification 
of SLE patients confirmed that there was a positive cor-
relation between the frequency of TIGIT-expressing 
CD3+CD4+ T lymphocytes and the SLEDAI score. But, 
TIGIT-expressing CD3+CD4+ T lymphocytes was not 
associated with other clinical features of patients with 
SLE including fever, cutaneous manifestations, oral 
ulcer, alopecia, arthritis, Raynaud’s phenomenon, effu-
sion and hematologic disorder. Thus, we established the 
correlation between the frequency of TIGIT-expressing 
CD3+CD4+ T lymphocytes and disease activity in SLE.
TIGIT is an inhibitory costimulatory molecule that 
mediates inhibitory signal in immune cells [8]. Consist-
ent with its inhibitory characteristics, the expression 
of TIGIT on NK cells was reported to be decreased in 
SLE patients [13]. Thus, from this point, the increased 
frequency of TIGIT-expressing CD3+CD4+ T lympho-
cytes in SLE seemed controversial to its function. How-
ever, evidences have also suggested that TIGIT might 
be involved in regulating B cell responses and promot-
ing antibodies production [38, 39]. In this study, we 
found that SLE specific autoantibody levels, such as anti-
dsDNA and anti-Sm, were positively correlated with the 
frequency of TIGIT-expressing CD3+CD4+ T lympho-
cytes. Thus, although the detail roles of TIGIT in SLE 
require further investigation, it seemed that besides func-
tions as an inhibitory costimulatory molecule, TIGIT 
might plays other roles in SLE. Evidences [12, 38] from 
recent reports indicated that TIGIT could expressed on 
different CD3+CD4+ T lymphocytes subsets, such as T 
regulatory (Treg) cells and follicular helper T (Tfh) cells, 
and the functions of TIGIT on different T lymphocytes 
subsets were different. While the exact role of Tregs and 
Tfh cells in human SLE has yet to be established, recent 
data suggests that Treg cells and Tfh cells may be dys-
regulated in more active SLE patients [26, 40]. Future 
work is necessitated to clarify the roles and mechanisms 
of TIGIT expressing CD3+CD4+ T lymphocytes in SLE, 
especially, the roles and mechanisms of TIGIT expressing 
Treg cells and Tfh cells.
Conclusions
To our knowledge, this is the first report on the charac-
teristics of TIGIT-expressing CD3+CD4+ T lympho-
cytes in SLE. Additionally, our research established a 
correlation between the frequency of TIGIT-expressing 
CD3+CD4+ T lymphocytes and disease activity of SLE, 
which might improves our understanding of the roles of 
CD3+CD4+ T lymphocytes in SLE.
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